The CIP2A protein was originally identified as p90, a cytoplasmic auto-antigen from the serum of a cancer patient. It was later found to inhibit protein phosphatase 2A (PP2A) activity as well as interact with c-myc. CIP2A's inhibitory activity blocks c-myc phosphorylation and its subsequent proteolytic degradation, producing a stable c-myc that promotes aberrant cell growth and transformation. In addition to its role in c-Myc stabilization, CIP2A promotes anchorage-independent cell growth and in vivo tumor formation. Not surprisingly, CIP2A is overexpressed in certain human malignancies and is classified as a proto-oncogene. Pallai et al used the CIP2A antibody to follow-up some of their earlier studies on cell-type specific CIP2A expression in various cancer cell lines1. In these later studies, they found that the transcription factors Ets1 and Elk1 modulate expression in cervical, endometrial, and liver cancer. There is a large amount of data related to the use of CIP2A as a biomarker in a wide variety of cancers and tumors. Bockelman’s group from Finland investigated the use of CIP2A as a marker in ovarian cancer with the CIP2A antibody, and found that it associates with poor survival and high grade/aggressiveness2.
-Immunocytochemistry-Immunofluorescence-NB110-59722-img0005.jpg)
Immunocytochemistry/Immunofluorescence: CIP2A Antibody
CIP2A is also a poor prognosis biomarker for colon cancer, as shown by Teng’s microarray and colony formation assay results with the CIP2A antibody in colon cancer cell lines3. He’s groups also used the CIP2A antibody to validate CIP2A as an independent marker for overall survival and disease-free survival in hepatocellular carcinoma (HCC) 4. Additionally, similar studies with the CIP2A antibody in bladder urothelial cell carcinoma (UCC) were recently published by Xue’s group5.
Novus Biologicals offers CIP2A reagents for your research needs including:
PMIDs
